<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04912271</url>
  </required_header>
  <id_info>
    <org_study_id>YBCSG-21-04</org_study_id>
    <nct_id>NCT04912271</nct_id>
  </id_info>
  <brief_title>Granisetron Transdermal Patch for Prophylaxis of Delayed CINV</brief_title>
  <official_title>Granisetron Transdermal Delivery System Versus Palonosetron in the Prevention of Delayed Chemotherapy-induced Nausea and Vomiting: a Phase 3 Non-inferiority Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transdermal granisetron has been shown to as effective as oral/ intravenous granisetron when&#xD;
      administered with or without dexamethasone. However, it has not been evaluated specifically&#xD;
      against the delayed response of chemotherapy-induced nausea and vomiting (CINV) in comparison&#xD;
      with palonosetron, as the complete response for the delayed phase was not reported in the&#xD;
      comparative study by Seol et al (Support Care Cancer 2016;24:945-952). Thus, transdermal&#xD;
      granisetron needs to be compared with palonosetron as part of dual and triple therapy in the&#xD;
      delayed phase of CINV.&#xD;
&#xD;
      This investigator-initiated study aims to compare the efficacy of granisetron transdermal&#xD;
      patch and palonosetron combined with NK-1 receptor antagonist and dexamethasone in the&#xD;
      prevention of delayed CINV in Chinese breast cancer patients who received high emetic or&#xD;
      moderate emetic chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 10, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 10, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete response (CR) in delay phase of CINV</measure>
    <time_frame>From 24 hours after initiating administration of chemotherapy agents to day 7 (24-168 hours)</time_frame>
    <description>To compare the complete response (CR) of Granisetron transdermal patch to Palonosetron (complete response is defined as no vomiting and no rescue medication) in delay phase of CINV</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete response (CR) in the acute and overall phase of CINV</measure>
    <time_frame>From 24 hours after initiating administration of chemotherapy agents to day 7 (24-168 hours)</time_frame>
    <description>1. To compare the complete response (CR) of Granisetron transdermal patch to Palonosetron (complete response is defined as no vomiting and no rescue medication) in the acute and overall phase of CINV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete control (CC) in delay phase of CINV</measure>
    <time_frame>From 24 hours after initiating administration of chemotherapy agents to day 7 (24-168 hours)</time_frame>
    <description>2. To compare the complete control (CC) of Granisetron transdermal patch to Palonosetron (complete control is defined as no vomiting, mild nausea and no rescue medication) in delay phase of CINV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete control (CC) in the acute and overall phase of CINV</measure>
    <time_frame>From initiating administration of chemotherapy agents to day 1 (0-24 hours) and day 7 (0-168 hours)</time_frame>
    <description>3. To compare the complete control (CC) of Granisetron transdermal patch to Palonosetron (complete control is defined as no vomiting and no rescue medication) in the acute and overall phase of CINV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' satisfaction with antiemetic therapy (assessed using a 10-cm visual analog scale at the time of patch removal</measure>
    <time_frame>7 days</time_frame>
    <description>&quot;dissatisfied&quot; on the left end (0 cm) of visual analog scale and the &quot;very satisfied&quot; on the right end of visual analog scale (10 cm)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Chemotherapy-induced Nausea and Vomiting (CINV)</condition>
  <arm_group>
    <arm_group_label>Granisetron transdermal patch (other name: sancuso), aprepitant or fosaprepitant, dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received granisetron transdermal patch plus dexamethasone followed by oral aprepitant or fosaprepitant infusion Granisetron transdermal patch Aprepitant 125 mg PO D1, 80 mg PO D2-D3; Fosaprepitant 150 mg IV D1 Dexamethasone 7.5-10 mg IV/PO D1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Palonosetron, aprepitant or fosaprepitant, dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received intravenous palonosetron plus dexamethasone followed by oral aprepitant or fosaprepitant infusion Palonosetron 0.25 mg IV D1 Aprepitant 125 mg PO D1, 80 mg PO D2-D3; Fosaprepitant 150 mg IV D1 Dexamethasone 7.5-10 mg IV/PO D1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granisetron transdermal patch</intervention_name>
    <description>Granisetron transdermal delivery system (GTDS) is the first 5-HT3 drug to be transdermally delivered and represents a convenient alternative to oral and intravenous antiemetics for the treatment of chemotherapy-induced nausea and vomiting.</description>
    <arm_group_label>Granisetron transdermal patch (other name: sancuso), aprepitant or fosaprepitant, dexamethasone</arm_group_label>
    <other_name>sancuso</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron</intervention_name>
    <description>Palonosetron is a second-generation 5-HT3 receptor antagonist with proposed higher efficacy and sustained action for prophylaxis of postoperative nausea and vomiting (PONV).</description>
    <arm_group_label>Palonosetron, aprepitant or fosaprepitant, dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant</intervention_name>
    <description>Aprepitant is a licensed treatment for nausea and vomiting, which blocks substance P activation of NK-1 (neurokinin 1) receptors.</description>
    <arm_group_label>Granisetron transdermal patch (other name: sancuso), aprepitant or fosaprepitant, dexamethasone</arm_group_label>
    <arm_group_label>Palonosetron, aprepitant or fosaprepitant, dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosaprepitant</intervention_name>
    <description>Fosaprepitant is a neurokinin-1 receptor antagonist, approved for the prevention of chemotherapy-induced nausea and vomiting.</description>
    <arm_group_label>Granisetron transdermal patch (other name: sancuso), aprepitant or fosaprepitant, dexamethasone</arm_group_label>
    <arm_group_label>Palonosetron, aprepitant or fosaprepitant, dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone, one of the glucocorticoids, has been suggested as a first-line drug for preventing low-level emetogenic chemotherapy- and radiotherapy-induced nausea and vomiting.</description>
    <arm_group_label>Granisetron transdermal patch (other name: sancuso), aprepitant or fosaprepitant, dexamethasone</arm_group_label>
    <arm_group_label>Palonosetron, aprepitant or fosaprepitant, dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female aged ≥ 18 years;&#xD;
&#xD;
          2. Pathologically confirmed breast cancer;&#xD;
&#xD;
          3. The physical status score ECOG ≤ 2;&#xD;
&#xD;
          4. Life expectancy of ≥3 months;&#xD;
&#xD;
          5. Patients first or had already received chemotherapy;&#xD;
&#xD;
          6. Patients scheduled to receive HEC/MEC chemotherapy, and the main emetic drugs will be&#xD;
             used within a single day;&#xD;
&#xD;
          7. Patients first use of granisetron transdermal patch;&#xD;
&#xD;
          8. In accordance with the indication of chemotherapy and basic requirements;&#xD;
&#xD;
               -  Peripheral haematology: Hb ≥8.0g/dL; absolute neutrophil count≥1.5×109/L;&#xD;
                  platelet count ≥80×109/L&#xD;
&#xD;
               -  Blood biochemistry: Total bilirubin &lt; 1.5×ULN, ALT and AST ≤ 2.5×ULN; if liver&#xD;
                  metastasis, ALT and AST &lt; 5×ULN, creatinine ≤ 1.5×ULN&#xD;
&#xD;
          9. Patients voluntarily participate and sign the informed consent form;&#xD;
&#xD;
         10. Be able to read, understand and complete patient diaries independently.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindicated to 5-HT receptor antagonists, NK-1 receptor antagonist or&#xD;
             dexamethasone;&#xD;
&#xD;
          2. Patients have used 5-HT receptor antagonist, NK1 receptor antagonist or any study&#xD;
             drugs within 4 weeks before chemotherapy&#xD;
&#xD;
          3. Any nausea and vomiting (II or above) within 72 hours before the start of&#xD;
             chemotherapy;&#xD;
&#xD;
          4. According to the judgment of the investigators, there are concomitant diseases&#xD;
             (including but not limited to hypertension, severe diabetes, active infection, thyroid&#xD;
             disease, etc.) that seriously endanger the safety of the patient or affect the&#xD;
             completion of the study;&#xD;
&#xD;
          5. Patients scheduled to receive radiotherapy of whole body, brain or upper abdomen;&#xD;
&#xD;
          6. Confirmed by craniocerebral CT or MRI, patients with brain tumor lesions or patients&#xD;
             taking drugs to treat brain tumors or epileptic symptoms;&#xD;
&#xD;
          7. History of drug abuse and alcohol dependence;&#xD;
&#xD;
          8. Pregnancy, lactation or intended pregnancy;&#xD;
&#xD;
          9. History of allergic reactions to drugs with similar chemical structures, or to&#xD;
             transdermal therapeutic systems, including commercial dressings such as Elastoplast®&#xD;
&#xD;
         10. Unable to swallow, having intestinal obstruction, or other factors that affect the&#xD;
             taking and absorption of the drug;&#xD;
&#xD;
         11. Long-term use of any inhibitors or inducers of CYP3A4, or take these drugs within 4&#xD;
             weeks before the first day of chemotherapy;&#xD;
&#xD;
         12. Other situations evaluated by investigators as unsuitable for enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jian Zhang, MD,PhD</last_name>
    <phone>+8664175590</phone>
    <phone_ext>85000</phone_ext>
    <email>syner2000@163.com</email>
  </overall_contact>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2021</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>delayed CINV</keyword>
  <keyword>granisetron transdermal delivery system</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Palonosetron</mesh_term>
    <mesh_term>Granisetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

